OWADAYS, using intensive front-line multiagent chemotherapy along with improved supportive care, more than 95% of children with acute lymphoblastic leukemia (ALL) can achieve a complete remission (CR), of whom 70% will remain in continuous CR and be considered cured.'-3 These results show the tremendous improvement in the development of more effective chemotherapy regimens for childhood ALL, which was once a fatal d i~e a s e .~ Nevertheless, current protocols fail in the remaining 30% of the children with newly diagnosed ALL, with bone marrow relapses representing the most common treatment failures.'-3 Second remissions can be induced with intensified chemotherapy in more than 90% of the children with ALL whose disease relapsed while they were on modem protocols, but their long-term prognosis is p~o r . ' .~.~ Long-lasting second hematologic remissions can be expected in about 10% of the children with early relapses and in up to 30% of those with late relapses, despite even more intensive second-line therapy that includes the effective front-line drugs used in an alternative Knowledge about the nature of relapsed ALL is limited, but it is assumed that regrowth of drug-resistant leukemic cells plays an important role. 6 It is unknown to which drugs and to what extent relapsed leukemic cells express resistance, mainly because a suitable drug-resistance assay was lacking until recently. The poor growth capacity of ALL cells in vitro, limiting the use of long-term clonogenic assays, could be circumvented with the introduction of so-called shortterm cell culture drug-resistance assay^.^ The 3-[4,5-dimethyl-thiazol-2,5-diphenyl] tetrazolium bromide (MTT) assay, first described by Black and Speer in 1954' and revised by Mosmann in 1983: has been adapted by us for testing ALL cells."." The 4-day semiautomated MTT assay is an efficient tool for large-scale drug-resistance testing and results showed a good correlation with the prognosis in childhood We present here the results of in vitro drugresistance testing on samples from 141 children with relapsed or refractory ALL. tial ALL cells, whereas the resistance ratios for the other drugs differed from 0.8-to 1.9-fold. lntraindividual comparisons between initial and relapsed samples from 16 children with ALL showed that both de novo and acquired drug resistance were involved. Specific in vitro drug-resistance profiles were associated with high-risk relapsed ALL groups. In vitro drug resistance was also related to the clinical response to chemotherapy in relapsed/refractory childhood ALL. We conclude that drug resistance may explain the poor prognosis for children with relapsedlrefractory ALL. These data may be helpful to design alternative treatment regimens for relapsed childhood ALL.
N MATERIALS AND METHODS

Patients
0 1995 by The American Society of Hematology. and 4 samples from children with refractory initial ALL. Cells from 16 children were tested both at initial diagnosis and at relapse. Diagnosis of ALL was based on morphologic evaluation of counterstained bone marrow (BM) smears and cytochemical staining (<3% myeloperoxidase positive blasts), complemented by immunophenotyping in most cases. AIL children have relapsed on modem intensive front-line multidrug regimens, with the far majority on Berlin-Frankfurt-Munster (BFM) or BM-oriented protocols, including combinations of glucocorticoids, vinca-alkaloids, anthracyclines, L-asparaginase, antimetabolites, cyclophosphamide, and, in some cases, ifosfamide and epipodophyllotoxin~.'~~'~ The distribution of the disease status and treatment regimens are shown in Table 1 . Response to ALL-REZ BFM 90 was evaluated and a second CR was defined as nonnocellular BM containing less than 5% blasts without extramedullary leukemia.
Part of the children were pretreated with an investigational window of idarubicin (IDA) in an ongoing phase I1 trial. No cytostatic treatment was administered 14 days before the infusion of IDA at 24 mg/m2/48 h. The response was evaluated 2 to 3 weeks after the administration of IDA. The following responses were defined: stable or progressive disease (grade 0), reduction of lymphoblasts in the peripheral blood (PB) or BM that still contained 2 2 5 % lymphoblasts (grade l), BM containing 25% but <25% lymphoblasts (grade 2), and CR (grade 3).
In the present study, the in vitro drug-resistance results of 141 samples from children with initial ALL tested between 1989 and 1993 were used as a historical comparison group. The majority of these initial ALL samples (n = 128) were the subject of a prospective Relapse statushreatrnent unknown 7
Children with initially diagnosed ALL. t Relapse 518 months from initial diagnosis.
* Relapse more than 18 months from initial diagnosis. study reporting on the relationship between in vitro drug resistance and progn~sis.'~ Leukemic samples. BM andor PB samples were collected with informed consent at Dutch centers from participants of the Dutch Childhood Leukemia Study Group (DCLSG) and at German, Austrian, and Swiss centers from participants of the ALL BFM Relapse Study Group. Samples were shipped by overnight express to our laboratory and processed within 36 hours after collection. Mononuclear cells were separated by Ficoll density gradient centrifugation (Lymphoprep; density, 1.077 g/mL; Nycomed Pharma, Oslo, Norway), washed twice, and resuspended in RPM 1640 (GIBCO-BRL, Breda, The Netherlands) containing 20% fetal calf serum. Sixteen samples were further treated with immunomagnetic beads directed against contaminating nonmalignant cells." The mean percentage of lymphoblasts (range) from these 16 samples increased from 69% (33% to 86%) to 90% (82% to 96%). All cell cultures contained 280% lymphoblasts at day 0 and control cell cultures contained 270% lymphoblasts at day 4, which is obligatory for a valid evaluation of drug resistance." BM and PB samples do not differ signiticantly with respect to in vitro drug resistance."
In vitro drug-resistance testing. In vitro drug resistance was assessed with the M l T assay." Briefly, 96-well microculture plates contained 100-pL cell suspensions (0.8 to 1.6 X lo6 cells/mL), with 6 concentrations of each drug in duplicate. The following drugs and range of concentrations were tested: prednisolone (PRED; 0.05 to 2,000 pg/mL); dexamethasone (DEXA; 0.0002 to 6 pdmL); vincristine (VCR 0.05 to 50 pg/mL); vindesine (VDS; 0.05 to 50 pg/mL); L-asparaginase (L-ASP; 0.003 to 10 IU/mL); daunorubicin (DNR; 0.002 to 2 pg/mL); doxorubicin (DOX; 0.008 to 8 pg/mL); IDA (0.002 to 2 pg/mL); cytarabine (AM-C; 0.002 to 2.5 pg/mL); 6-thioguanine (6-TG; 1.56 to 50 pg/mL); 6-mercaptopurine (6-MP 15.6 to 500 pg/mL); etoposide (VP16; 0.05 to 50 pg/mL); teniposide (VM26; 0.003 to 8 pg/mL); and 4-hydroperoxy-ifosfamide (IFO; 0.1 to 100 pg/mL), an active metabolite of ifosfamide, kindly provided by ASTA Pharma AG (Dr M. Peukert, Bielefeld, Germany). Methotrexate was not tested because this drug is not cytotoxic to ALL cells in short-term assays such as the MTT assay.'' Untreated control cells were cultured sixfold. After 4 days of incubation in 5% carbon dioxide at 37°C in a humidified incubator, 10 p L of 5 mg/ mL MTT (Sigma, St Louis, MO) was added to each well and the microculture plates were subsequently incubated for 6 hours. The yellowish tetrazolium salt MTT is reduced to dark-colored formazan by viable cells only. Formazan crystals were dissolved with 100 FL of acidified isopropanol. The optical density (OD) was measured at 565 nm with an EL-3 12 microplate reader (Biotek Instruments Inc, Winooski, VT). The OD is linearly related to the number of viable cells. 18 The leukemic cell survival (LCS) was calculated as follows: LCS = (ODdmg-explwed well f mean ODco.trol wells) x 100%. The LC50 (the drug concentration lethal to 50% of the cells) was used as measure for drug resistance. Individual in vitro drug-resistance protiles are reproducible. Comparable results were obtained on paired fresh and cryopreserved samples of 11 patients and also after repeated (n = 6 ) testing of the same sample; 295% of the LCso values (156 observations) were distributed within one dilution step of the concentration range (data not shown).
Statistics. The LCs0 values were nonparametrically distributed. Differences in the distribution of LC50 values were tested using the Mann-Whitney U test and the Wilcoxon matched-pairs signed-ranks test at a two-tailed significance level of .05. The Spearman rank correlation test (correlation coefficient, p ) was used to analyze the relationship of LCso values between several drugs. In case LCso values were higher than the maximum or lower than the minimum concentration tested, the highest or lowest concentration was used as LCs0 for statistical analysis.
RESULTS
Relapsed versus initial ALL: A group comparison.
We compared the LC50 values of 141 initial and 137 relapsed ALL samples, as summarized in Table 2 . Large interpatient variations of LC50 values were found, ie, even more than 5 logs for PRED, with LC50 values ranging from less than 0.05 to more than 2,000 pg/mL. The LC50 values of the initial ALL group and the relapsed ALL group almost totally overlapped. However, the group of relapsed ALL samples was more resistant to PRED, DEXA, DNR, DOX, L-ASP, 6-TG, and 6-MP than the group of initial ALL samples; no statistical differences were found for VCR, VDS, ARA-C, IFO, VM26, and VP16. The distribution of LCso values of initial and relapsed ALL samples for PRED is shown in Fig 1. The LC50 value for PRED was higher than its maximum concentration used (2,000 pg/mL) in 11 of 107 initial ALL samples compared with 48 of 106 relapsed ALL samples (LC5o set at 2,000 pg/mL in Fig 1) .
Resistance ratios were calculated for each drug by dividing the median LC50 value of the relapsed ALL group by the median LC,, value of the initial ALL group ( Table 2) . A pronounced resistance to glucocorticoids was found. The relapsed ALL group was median 357-fold and greater than 24-fold more resistant to PRED and DEXA, respectively, compared with the initial ALL group. The resistance ratios for the other drugs ranged from 0.8 to 1.9.
The LC50 values for all drugs tested were positively corre- ( p = .77; p = .25 to .71 for epipodophyllotoxins versus the other drugs). Relapsed versus initial ALL: Individual comparisons. Results were obtained on both initial and relapsed ALL samples from 16 children. We tested 12 pairs under identical conditions using cryopreserved cells; 4 pairs were tested at different occasions. Analysis of these paired samples showed that relapsed samples were more resistant to glucocorticoids ( P = .OOl) and to DNR (P = .01). No significant differences were found for VCR, L-ASP, ARA-C, 6-TG, and VM26. We had not tested VDS, DOX, 6-MP, IFO, and VP16.
In Fig 2, paired LC50 values for PRED and DEXA, VCR, L-ASP, and DNR are shown, and also the median and range of LC50 values for both groups of initial and relapsed ALL as reference data. LC50 values for glucocorticoids increased in 12 of 15 samples, whereas the other 3 samples were already de novo resistant (defined as LC50 sample ==median LC50 of the initial ALL group). In 6 of 9 samples, de novo resistant to glucocorticoids, LCso values further increased. LCso values for DNR increased in 11 of 16 samples; in 12 of 16 samples at relapse, the LCso value was higher than the median LCso of the initial ALL group. No differences were observed for VCR and L-ASP in a group comparison of 3863 paired samples; however, some cases showed de novo and acquired resistance to either drug and also, in contrast to glucocorticoids and DNR, decreased LCso values for VCR and L-ASP at relapse were observed.
Relapse status and drug resistance. We have tested 73 children at first relapse; 44 early relapses defined as a relapse S 18 months from diagnosis and 29 late relapses defined as a relapse more than 18 months from diagno~is.'~ Another 57 children were tested at a second or subsequent, ie, multiple, relapse. In 7 cases the relapse status could not be identified. The LCso values of the early, late, and multiple relapse groups are summarized in Table 3 . Ratios of median LCso values from the early or the multiple relapse groups were calculated relative to the prognostically more favorable late relapse group. The early relapse group was 2.4-and 2.0-fold more resistant to the vinca-alkaloids VCR and VDS, respectively, as compared with the late relapse group ( P I .Ol). The relation between VCR resistance and time from diagnosis until first relapse is shown in Fig 3. Also, for all other drugs, except VP16 and VM26, the early relapse group was more resistant than the late relapse group (ratios ranged from 1.3 to 11.4), but not statistically significant. The multiple relapse group was more resistant to DEXA, VCR, L-ASP, DOX, and 6-MP compared with the late relapse group (P < .05); for the other drugs, ratios were also greater than 1 but not statistically significant. Epipodophyllotoxins are second-line drugs usually used for the first time in the treatment of relapsed ALL. The in vitro resistance did not differ between initial, early, and late relapsed ALL, but the multiple . . .
relapse group was 2.0-and 1.5-fold more resistant to VM26 and VP16, respectively, compared with the first (early and late) relapse group (P < .05).
BFM front-line chemotherapy is electively ceased after 24 months from diagnosis in various risk groups. Thus, samples of the early relapse group were obtained during cytostatic treatment, which might influence the in vitro drugresistance results. Samples of 2 children with first relapsed ALL refractory to intensive reinduction therapy were tested at diagnosis of relapse while off therapy and later on while cytostatic treatment had been administered for 2 weeks and 2 months, respectively. Compared with the first samples tested, we observed a decrease in 15 of 18 LC50 values obtained on samples collected during cytostatic treatment; 3 of 18 LCso values did not alter. Thus, the level of in vitro resistance obtained on samples collected during cytostatic treatment may be underestimated.
Clinical response and drug resistance. Four children with initial ALL were refractory to induction therapy with PRED, VCR, L-ASP, and DNR. Although these samples were obtained during intensive chemotherapy, they were highly resistant to these classical front-line drugs, except for case 6560, who was relatively sensitive to L-ASP and ARA-C (Fig 4) . LC50 values were expressed in percentiles compared with the initial ALL group. For example, the P75 indicates that a sample is more resistant to a drug than 75% of all samples of the initial ALL group. All 4 samples were relatively sensitive to 6-TG; thiopurines play a major role in maintenance therapy.
The clinical response was evaluable in 30 of 35 children with relapsed ALL who were treated according to the ALL-REZ BFM 90 protocol ( Table 4) . Six of 30 children failed to achieve a second CR. Cells from these children were greater than 13.3-and greater than 1. ing effective front-line drugs, results in a poor progno~is'.~.~ when compared with newly diagnosed childhood ALL.'" A more detailed insight regarding drug resistance might be used as a rationale to develop more effective treatment regimens for these patients. Although the low proliferative capacity of ALL cells in vitro limited their use for clonogenic assays, this problem could be bypassed using short-term cell culture drug-resistance assays, such as the MTT assay.7 These assays are based on measuring total cell kill of both proliferating and nonproliferating cells and, in fact, measure the end effect of actual resistance mechanisms. However, the "IT assay cannot discriminate between malignant and nonmalignant cells and, because the latter are significantly more drug resistant, they may lead to an overestimation of drug resistance.""* Samples evaluated in the present study all met the requirements for a valid evaluation of drug resistance and contained ~8 0 % lymphoblasts at the start and 270% at the end of the cell culture." Clinical relevant data, assessed with the MTT assay, have emerged in newly diagnosed childhood ALL as in vitro drug resistance appeared to be related to prognosisL2," and to specific risk groups defined by age and immunophenotype, myeloid markers, and DNA ploidy.20~22 Results of the present study may shed more light on the role of drug resistance in relapsed childhood ALL because it was shown that lymphoblasts from children with relapsed ALL were in vitro more resistant to most frontline drugs when compared with those of a historical control group of children with newly diagnosed ALL. Both de novo and acquired resistance were involved, as suggested by a KLUMPER ET AL comparison of 16 paired samples taken at diagnosis and at relapse. Also, in vitro drug resistance was related to the relapse status and to the response to chemotherapy. Compared with a historical control group of children with initial ALL, children with relapsed ALL were in vitro more resistant to 3 of 4 classes of drugs widely used for remission induction therapy (glucocorticoids, anthracyclines, and L-ASP) and also more resistant to thiopurines, which are widely used in maintenance therapy and important for a long-lasting CR. A strong cross-resistance existed between PRED and DEXA, between DNR and DOX, and between 6-TG and 6-MP. Thus, children with relapsed ALL were in vitro relatively resistant to several important front-line drugs. The relative concept of in vitro drug resistance must be emphasized. Leukemic cell kill can still be induced in drugresistant samples, although higher concentrations are required as compared with in vitro sensitive samples. This indicates that higher doses of previously used agents may be needed to treat patients with relapsed ALL, but excessive toxicity may limit further dose intensification. Based on our results, it would appear more rational to use vinca-alkaloids, ARA-C, IFO, and epipodophyllotoxins for the treatment of relapsed childhood ALL, because resistance to these drugs did not differ between initial and relapsed ALL samples. The effectiveness of combinations of ARA-C and epipodophyllotoxins has been reported in the treatment of late relapses." The present data also suggest that the treatment history may be very informative, because resistance was predominantly present against previously used front-line drugs, whereas second-lines drugs were less frequently involved.
Cells of children with relapsed ALL expressed the highest level of resistance to glucocorticoids, which are known to be the most effective single agents in the treatment of initial childhood ALL, with response rates of 75% to 90%.23 Re- lapsed ALL cells were about 300-fold more resistant to PRED when compared with initial ALL cells. Nevertheless, steroids may still be very useful agents for the treatment of relapsed ALL and, in fact, are widely used in BFM relapse protocols. Even in the most resistant cases, ie, those unable to induce 50% in vitro cell kill at the maximum concentration tested, a leukemic cell kill up to 30% to 40% is commonly observed. This latter response can still be very significant and may clinically be achieved without limiting high doses of other drugs due to the favorable nonoverlapping toxicity profile of glucocorticoids versus other drugs. Resistance to the other drugs was less striking and varied only about twofold. However, a twofold resistance, eg, to DNR, may be of clinical irnportan~e.'**'~ Doubling the dose of DNR could overcome drug resistance theoretically, but would lead to unacceptable toxicity when administered as part of intensive combination chemotherapy. Also, the resistance ratios reported here may be underestimated, because results suggested that lower LC50 values were determined on samples collected during treatment with cytostatic drugs. A significant part of the samples from children with relapsed ALL in this study was collected while these children were receiving cytostatic treatment.
LCso values of samples from initial and relapsed ALL overlapped significantly indicating that some children are already drug resistant at initial diagnosis. It is well known from early single-agent studies during the development of ALL treatment that a proportion of children with initial ALL were not responsive to single drugs." De novo resistance to specific classes of drugs has been overcome by combination chemotherapy. On the other hand, part of the relapsed ALL samples were still in vitro sensitive to drugs. Indeed, with intensive reinduction therapy, more than 90% of the children with relapsed ALL can be brought into a second CR, but only one third of them will achieve a long-lasting second CR.4.' Earlier studies have shown that de novo in vitro resistance is of clinical importance. When children with ALL at initial diagnosis were divided into a resistant and a sensitive group by the median LC50 value of specific drugs, the risk of relapse was significantly higher in the resistant In the present study, we showed that, besides this de novo resistance, acquired resistance also plays an important role, especially to glucocorticoids and to DNR. This was shown by intraindividual comparisons of in vitro drug resistance at initial diagnosis and at relapse. In 6 of 9 samples, de novo resistance to PRED or DEXA further increased, whereas 6 de novo sensitive samples acquired resistance to DEXA. Whether acquired resistance is caused by regrowth of a small subclone intrinsically resistant at diagnosis or by mutation of de novo sensitive cells remains unsolved. The MTT assay determines in vitro resistance of dominant clones and is not capable of detecting small resistant subclones.
Children with early relapsed or with multiple relapsed ALL were reported to have a very poor progno~is."*~*'~ In the present study, we showed that, compared with the prognostically more favorable late relapsed ALL group, early relapsed ALL samples were more resistant to vinca-alkaloids, whereas the multiple relapse ALL group showed a significantly broader spectrum of resistance to drugs, eg, DEXA, VCR, L-ASP, DOX, and 6°F'. The median LC5o values for all drugs, except for epipodophyllotoxins, obtained on early or multiple relapsed ALL samples were higher compared with the late relapsed ALL group, although not all differences reached statistical significance. These results might be underestimated due to the fact that most poor prognostic relapsed ALL samples were collected during chemotherapy. Epipodophyllotoxins are second-line drugs usually used for the first time in the treatment of relapsed ALL. In vitro resistance to these drugs did not differ between initial ALL and early and late relapsed ALL, but multiple relapsed ALL samples were about twofold more resistant to epipodophyllotoxins than the group of first (early and late) relapsed ALL samples. This finding suggests that specific drug resistance may be induced by previous treatment.
Finally, in vitro drug resistance was related to the response to chemotherapy. Because of the wide variation in treatment and because, in general, poor prognostic groups were tested for whom no protocols were at hand, only a limited number of vitro/vivo correlations could be evaluated. Children at initial diagnosis refractory to front-line treatment were, in general, highly resistant to drugs used for remission induction. Children with relapsed ALL who were relatively in vitro resistant to glucocorticoids and anthracyclines were more likely to be poor responders to ALL-REZ BFM 90 therapy. Poor responders to IDA monotherapy window were in vitro median 3.2-fold more resistant to IDA than good responders.
In summary, these results show that children with relapsed ALL are relatively resistant to most front-line drugs (most pronounced to glucocorticoids) and that both de novo and acquired resistance are involved. Moreover, in vitro drug resistance was related to very poor prognostic relapsed ALL subgroups and to the response to chemotherapy. We conclude that in vitro drug resistance may explain the poor prognosis in relapsed and refractory childhood ALL. This knowledge might contribute to the design of better treatment protocols for relapsed childhood ALL.
